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INTRODUCTION
Deficiency of von Willebrand factor-cleaving protease,
a disintegrin-like and metalloprotease with thrombospon-
din type 1 motif 13 (ADAMTS13) is thought to be res-
ponsible for platelet aggregation and microthrombi forma-
tion, which in turn cause the development of typical
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thrombotic microangiopathies (1). This deficiency is found
in patients with thrombocytopenia-associated multiple
organ failure such as thrombocytopenic purpura, hemolytic
uremic syndrome, or sepsis (2-6). Disseminated intravas-
cular coagulation (DIC) is a microangiopathic phenotype
characterized by increased tissue factor (TF) and plasmino-
gen activator inhibitor type I (PAI-1), unopposed by the
anticoagulant proteins tissue factor pathway inhibitor
(TFPI), protein C, antithrombin III, and prostacyclin (6, 7).
The severest forms also have an ADAMTS 13 deficiency
(8). We evaluated the clinical significance of ADAMTS13
deficiency in patients with sepsis-induced DIC.
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Background :Deficiency of von Willebrand factor-cleaving protease, a disintegrin-like and metallo-
protease with thrombospondin type 1 motif 13 (ADAMTS13), is thought to be responsible for platelet
aggregation and microthrombi formation, which in turn cause typical thrombotic microangiopathies.
This deficiency is found in patients with thrombocytopenia-associated multiple organ failure such
as thrombocytopenic purpura and disseminated intravascular coagulation (DIC). We evaluated the
clinical significance of ADAMTS13 deficiency in patients with sepsis-induced DIC.
Materials and Methods :Nineteen patients with sepsis-induced DIC were enrolled. ADAMTS13 anti-
gen levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and activity levels
were measured by fluorescence resonance energy transfer assay. Patients were categorized into
two groups according to ADAMTS13 antigen level: less than 350 ng/mL or above. Clinical charac-
teristics and survival were compared between the two groups.
Results :ADAMTS13 antigen level was less than 350 ng/mL in 7 patients and was above 350 ng/mL
in 12 patients. There were no significant differences between the groups for age, sex, severity of
illness, and other clinical characteristics. In patients with ADAMTS13 antigen level less than 350
ng/mL, in-hospital mortality was much higher (100% versus 25%, P=0.003) and 7-day survival was
much shorter (P=0.023).
Conclusion :Deficiency of ADAMTS13 could be thought to be associated with unfavorable outcome
in patients with sepsis-induced DIC.
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MATERIALS AND METHODS
1, Study population
From September 2005 to December 2005, 19 patients
with sepsis-induced DIC were enrolled at Konyang Uni-
versity Hospital, 813-bed teaching hospital located in
Dajeon, Korea. Since the normal value of ADAMTS13
antigen level defined by manufacturer's instruction was
less than 350 ng/mL, patients were categorized into two
groups accordingly: the ADAMTS13 antigen level less
than 350 ng/ml or above. Clinical characteristics and sur-
vival were compared between the two groups.
2. Diagnosis of sepsis and DIC
The diagnosis of sepsis was made according to the
definition of the American College of the Chest Physicians/
Society of Critical Care Medicine Consensus Conference
Committee (9). The diagnosis of DIC was made according
to the criteria established by the Japanese Ministry of
Health and Welfare (1988), which are described elsewhere
(10). Briefly, the presence of underlying diseases (infection
or malignancies), specific clinical conditions (bleeding or
organ dysfunction), and results of laboratory examinations
(platelet counts, prothrombin time, fibrinogen, and/or fibrin
degradation products) were quantified based on the score.
If the score was 7 or more, the diagnosis of DIC was made.
The severity of illness of the patients was evaluated
according to the Acute Physiology and Chronic Health
Evaluation II (APACHE II) (11).
3. Measurement of ADAMTS13
ADAMTS13 antigen levels were determined by
IMUBINDⓇ ADAMTS13 ELISA kit (America Diagnostica
Inc, Stamford, CT, USA). ADAMTS13 activity levels were
measured by fluorescence resonance energy transfer assay
described previously (12).
4. Statistical analysis
The clinical characteristics were compared using the
Mann-Whitney U test and Fisher's exact test depending
on the scales of measurement. Survival was evaluated
using Kaplan-Meier method. All P values were two-
tailed, and P<0.05 was considered to be statistically sig-
nificant. All analyses were performed using Statistical
Package for the Social Sciences (SPSS) 11.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
1. Demographic characteristics of patients
Among enrolled 19 patients, the level of ADAMTS-13
was below 350 ng/mL in 7 patients and above 350 ng/mL
in 12 patients. Age, sex, and severity index of illness such
as the presentation of septic shock and APACHE II score
between the two groups did not show statistically signifi-
cant differences (Table 1). The number of cases of micro-
biologically defined infections was 15 patients (79%). The
causes of infections were pneumonia, intra-abdominal in-
fections, and urinary tract infection in decreasing order of
frequency; there were no differences in the cause of infec-
tion between the two groups (Table 1). The activity of
ADAMTS-13 was below 70% in 6 patients; 3 patients (25
%) were from the groupwhose level of ADMAMTS-13was
>350 ng/mL and 3 (42.9%) patients were from the group
whose level of ADMAMTS-13 was ≤350 ng/ml. There
were no differences between the two groups (Table 1).
2. Mortality according to the level of ADAMTS-13
Nine patients died of sepsis within 7 days after admis-
sion. Seven-day mortality rate was 25.0 % (3 of 12) in the
group with the levels of ADMAMTS-13 >350 ng/ml, and
85.7% (6 of 7) in the group with the levels of ADMAMTS-
13 ≤350 ng/mL (Table 1). Log rank test using Kaplan-
Meyer methods revealed that 7-day survival was much
shorter in patients with ADAMTS13 antigen levels less
than 350 ng/ml (P=0.023) (Fig. 1).
DISCUSSION
ADAMTS-13 activity is decreased in thrombotic throm-
bocytopenic purpura, sepsis, idiopathic thrombocytopenic
purpura, heparin induced thrombocytopenia, liver cirrhosis,
leukemia, and systemic lupus erythematosus (4, 13-15). In
patients with sepsis, severe deficiency of ADAMTS-13
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was associated with renal failure (8) and/or sepsis-in-
duced thrombocytopenia and organ failure (15).
In this study, among patients with sepsis-induced DIC
in intensive care unit, all patients whose level of
ADAMTS13 was below 350 ng/mL died within 28 days, but
only 3 patients (25%) from 12 patients whose levels of
ADAMTS13 was above 350 ng/mL died. If cutoff value had
been 500 ng/mL, the 28-day mortality rate of the patients
with ADAMTS13 deficiency would be 75.0% (9/12) and the
mortality rate of the patients without ADAMTS13 de-
ficiency would be 14.3% (1/7). Therefore, the further study
is needed to define the cutoff value of ADAMTS13 as a
risk factor of mortality in patients with sepsis with DIC.
Ono and colleague reported that severe secondary de-
ficiency of ADAMTS13 in patients with sepsis-induced DIC
was correlated with development of renal failure (8). Also,
this study revealed that severe secondary deficiency of
ADAMTS13 in patients with sepsis-induced DIC was
associated with mortality. The underlying mechanism of
sepsis-induced thrombocytopenia and organ failure is not
well known, but it could be hypothesized that sepsis-as-
sociated thrombocytopenia results fromwidespread platelet
aggregation and thrombotic microangiopathy caused, in
part, by deficient proteolysis of ultra-large von Willebrand
factor (ULVWF) (15). ULVWF is cleaved by ADAMTS13
(16). Therefore, ADAMTS13 deficiency may play a role in
the sepsis-induced thrombocytopenia, organ failure, and
subsequent mortality. The restoration from the deficient
proteolysis of ULVWF could be achieved by plasma
exchange (17) and it could attribute to clinical improvement
in patients with severe sepsis if more studied are needed.
There are some prognostic indexes such as APACHE
Figure 1. Cumulative survival in patients with sepsis-induced DIC
according to the level of ADAMTS13.
Table 1. Comparison of Characteristics according to the Level of ADAMTS-13 in Patients with Sepsis-induced Disseminated
Intravascular Coagulation*
Characteristics
Level of ADAMTS-13 (ng/mL)
P†
>350 ng/mL (n=12) ≤350 ng/mL (n=7)
Baseline characteristics
Age (year, range)
Male sex (No., %)
Shock (No., %)
APAHCE II score (mean, range)
Leukocyte count (x109/L)
Platelet count (x109/L)
INR
Activity of ADAMTS-13 (<70%)
Infection (No., %)
MDI
Pneumonia
UTI
Intra-abdomial
Outcome
28-day mortality cases
7-day mortality cases
67 (39-83)
7 (58.3%)
7 (58.3%)
20 (10-24)
13.9 (6-77)
59 (30-219)
1.74 (1.01-2.93)
3 (25.0%)
9 (75.0%)
6 (50.0%)
2 (16.7%)
4 (33.3%)
3 (25.0%)
3 (25.0%)
65 (35-78)
5 (71.4%)
4 (57.1%)
19 (15-34)
10.2 (7-13)
48 (3-91)
1.73 (1.01-3.19)
3 (42.9%)
6 (85.7%)
5 (71.4%)
1 (14.3%)
1 (14.3%)
7 (100.0%)
6 (85.7%)
0.672
0.656
1.000
0.611
0.022
0.043
0.604
0.617
1.000
0.633
1.000
0.603
0.003
0.020
Abbreviations : ICU, intensive care unit; APACHE II, acute physiologic and chronic health evaluation II; INR, international normalized ratio; MDI,
microbiologic defined infection; UTI, urinary tract infection.
*Data are expressed as number (percentage) or median (range).
†Mann-Whitney U test for continuous variables and Fischer's exact test for categorical values.
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II score and Sequential Organ Failure Assessment (SOFA)
score for severe sepsis. The difference in severity index
of illness such as the presentation of shock and APACHE
II score between the two groups was not observed.
Therefore, the level of ADAMTS13 could be a significant
prognostic factor in patients with sepsis-induced DIC.
This study has some limitations such as small number
of subjects. However, this study revealed that secondary
deficiency of ADMATS13 in patients with sepsis-induced
DIC may be associated with unfavorable outcome. More
studies are needed if the restoration from the status of de-
ficient proteolysis of ULVWF could improve the survival
rate of patients with sepsis.
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